Head-To-Head Survey: RxSight (NASDAQ:RXST) & AxoGen (NASDAQ:AXGN)

RxSight (NASDAQ:RXST) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Earnings and Valuation

This table compares RxSight and AxoGen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.58 million	1.60	-$38.94 million	($1.13)	-4.34
AxoGen	$225.21 million	11.76	-$15.70 million	($0.68)	-72.43

AxoGen has higher revenue and earnings than RxSight. AxoGen is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

78.8% of RxSight shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 10.1% of RxSight shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares RxSight and AxoGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
AxoGen	-13.36%	-8.90%	-6.47%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for RxSight and AxoGen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3	7	2	0	1.92
AxoGen	1	2	12	0	2.73

RxSight presently has a consensus price target of $8.17, suggesting a potential upside of 66.78%. AxoGen has a consensus price target of $55.55, suggesting a potential upside of 12.78%. Given RxSight’s higher possible upside, analysts clearly believe RxSight is more favorable than AxoGen.

Risk and Volatility

RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Summary

AxoGen beats RxSight on 11 of the 14 factors compared between the two stocks.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.